{"id": 225026466, "title": "Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS\u00ae from Major Insurance Carrier", "text": "PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (\u201cmmTBI\u201d) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com. Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cgoal,\u201d \u201caim\u201d and similar expressions. Such forward-looking statements include, among others, statements regarding the Company\u2019s ability to negotiate acceptable reimbursement rates with additional third-party payers, the potential for patients to submit additional claims with other third-party payers, and the uses and effectiveness of PoNS and PoNS Therapy.", "summary": "&#8212; Reimbursement at $23,900, slightly below list price &#8212; &#8212; Represents a significant milestone toward increasing accessibility of PoNS &#8212; NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) &#8212; Helius Medical Technologies, Inc. (Nasdaq:HSDT) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced [&#8230;]", "url": "https://financialpost.com/globe-newswire/helius-medical-technologies-inc-announces-third-party-reimbursement-for-pons-from-major-insurance-carrier", "image": "https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2024/05/commuters-on-bay-street-as-canadian-stocks-mixed.jpg?quality=5&strip=all&w=100&sig=gCsOruxPhrA8bPqdSVYb6g", "video": null, "publish_date": "2024-05-29 13:15:08", "author": "GlobeNewswire", "authors": ["GlobeNewswire"], "language": "en", "source_country": "CA", "sentiment": -0.106}